{"id":30323,"date":"2025-03-31T15:36:52","date_gmt":"2025-03-31T05:36:52","guid":{"rendered":"https:\/\/template.reachmarkets.com.au\/investorportal\/?p=30323"},"modified":"2025-03-31T15:38:00","modified_gmt":"2025-03-31T05:38:00","slug":"prescient-therapeutics-investor-briefing-31-mar","status":"publish","type":"post","link":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/","title":{"rendered":"Prescient Therapeutics: Investor Briefing"},"content":{"rendered":"\n<section id=\"investor-briefing\" class=\"wp-block-gutentor-m3 section-gmc091118 gutentor-module gutentor-container-cover has-image-bg has-custom-bg\"><div class=\"grid-container\">\n<section id=\"gm81dae65\" class=\"wp-block-gutentor-m4 section-gm81dae65 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm5e7c9a\" class=\"wp-block-gutentor-m4-col col-gm5e7c9a gutentor-single-column  grid-lg-12 grid-md-12 grid-12\"><div id=\"section-gm5e7c9a\" class=\"section-gm5e7c9a gutentor-col-wrap\">\n<h2 class=\"wp-block-heading has-text-align-center has-white-color has-text-color\" style=\"font-size:33px\">Prescient Therapeutics: Investor Briefing with CEO James McDonnell<\/h2>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"gm706000b\" class=\"wp-block-gutentor-m4 section-gm706000b gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gmf04fe0\" class=\"wp-block-gutentor-m4-col col-gmf04fe0 gutentor-single-column  grid-lg-7 grid-md-6 grid-12\"><div id=\"section-gmf04fe0\" class=\"section-gmf04fe0 gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full showvi\"><img loading=\"lazy\" decoding=\"async\" width=\"650\" height=\"360\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png\" alt=\"\" class=\"wp-image-30326\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png 650w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3-300x166.png 300w\" sizes=\"auto, (max-width: 650px) 100vw, 650px\" \/><\/figure>\n\n\n\n<script src=\"https:\/\/ajax.googleapis.com\/ajax\/libs\/jquery\/3.5.1\/jquery.min.js\"><\/script>\n<script type=\"text\/javascript\"> \njQuery(document).ready(function ($) {\n    $('.showvi').click(function(e) {\n    e.preventDefault();\n  $('.showvi').html('<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/1070908494?title=0&#038;byline=0&#038;portrait=0\" width=\"100%\" height=\"410\" frameborder=\"0\" allow=\"autoplay; fullscreen\" allowfullscreen><\/iframe>');\n});\n});\n\n <\/script>\n<script type=\"text\/javascript\">jQuery(document).ready(function($){\n    $(\".showvi\").append(\"<img class='play-icon play-video' src='https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/playvideo-3-1.svg' \/>\");\n});<\/script>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm92d1ce\" class=\"wp-block-gutentor-m4-col col-gm92d1ce gutentor-single-column  grid-lg-5 grid-md-6 grid-12 homepage-custom\"><div id=\"section-gm92d1ce\" class=\"section-gm92d1ce gutentor-col-wrap\">\n<p class=\"has-white-color has-text-color\">CEO and Managing Director, James McDonnell, held an investor briefing with Reach Markets, where he discussed the next critical phase towards approval and commercialisation of PTX-100.<\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">In this session, James discusses how:<\/p>\n\n\n\n<ul class=\"wp-block-list white\">\n<li class=\"has-white-color has-text-color has-link-color wp-elements-df352dacac8ae4b1c0b845371ad8a30c\">How PTX-100\u2019s Phase 1b results \u2013 which significantly exceeded benchmark expectations and existing drugs \u2013 provide a strong basis as we move into Phase 2 clinical trials.<\/li>\n\n\n\n<li class=\"has-white-color has-text-color has-link-color wp-elements-8eb8b2c90f859001fa452efea0514623\">How the FDA\u2019s Orphan Drug Designation and its acceptance of the Phase 2 clinical trial could lead to a fast-track designation for PTX-100 and closer to commercialisation \u2013 with a A$1bn+ market in the US alone.<\/li>\n\n\n\n<li class=\"has-white-color has-text-color has-link-color wp-elements-e4de012a6d2f99e5b16799548ee44f5b\">Why PTX-100 is just one application of Prescient\u2019s much broader RAS Family inhibitor technology, which has potential applications for 22% of cancer cases world-wide.<\/li>\n<\/ul>\n\n\n\n<p><\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">Recorded on 31 March 2025 at 12pm (AEDT)<\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/\">Join the next Prescient Therapeutics webcast<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/register\/\">Register to stay up to date with Prescient Therapeutics<\/a><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"bio\" class=\"wp-block-gutentor-m3 alignwide section-gmd9a6b77 gutentor-module gutentor-container-cover custom-fullwidth\"><div class=\"grid-container\">\n<h4 class=\"wp-block-heading speak has-text-color\" style=\"color:#ffcc00\">Featured Speaker<\/h4>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-center speaker-heading has-white-color has-text-color\"><\/h3>\n\n\n\n<section id=\"gm34ff057\" class=\"wp-block-gutentor-m4 section-gm34ff057 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gmb8d2d4\" class=\"wp-block-gutentor-m4-col col-gmb8d2d4 gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gmb8d2d4\" class=\"section-gmb8d2d4 gutentor-col-wrap\"><\/div><\/div>\n\n\n\n<div id=\"col-gmea0931\" class=\"wp-block-gutentor-m4-col col-gmea0931 gutentor-single-column  grid-lg-6 grid-md-12 grid-12\"><div id=\"section-gmea0931\" class=\"section-gmea0931 gutentor-col-wrap\"><div class=\"wp-block-image speaker-img\">\n<figure class=\"aligncenter size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/James_McDonnell_PTX.png\" alt=\"\" class=\"wp-image-30282\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/James_McDonnell_PTX.png 300w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/James_McDonnell_PTX-150x150.png 150w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/figure>\n<\/div>\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-center speaker-heading has-white-color has-text-color\">James McDonnell<\/h3>\n\n\n\n<h4 class=\"wp-block-heading has-text-align-center speaker-title has-white-color has-text-color\">CEO<\/h4>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color has-link-color wp-elements-0aba452cf1d8bebf2edef94ef46c87df\">James McDonnell is a seasoned leader in the biopharmaceutical industry, bringing over 25 years of global experience in pharmaceuticals, with a particular focus on blood disorders and hematological malignancies such as Myeloma, Myelodysplasia, and CML.<\/p>\n\n\n\n<p class=\"has-text-align-center has-white-color has-text-color has-link-color wp-elements-12c94ad4e3d1dcb29a6617d0088acce4\">Throughout his career, James has held senior leadership roles at renowned pharmaceutical companies, including Pharmion and CSL Vifor. At Pharmion, he spearheaded the growth of its oncology and hematology portfolio as Head of Global Marketing, contributing significantly to the company\u2019s acquisition by Celgene Corporation for US$2.9 billion. Most recently, James served as Global Commercial Lead for Patient Blood Management at CSL Vifor, where he drove key enterprise-wide strategic initiatives.<\/p>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color has-link-color wp-elements-d9f476fae128ffa46777e5134fb445c9\">James is a registered pharmacist and a member of the Royal Pharmaceutical Society. He holds a Graduate Diploma in Marketing from Monash University and is a graduate of the Australian Institute of Company Directors.<\/p>\n<\/div><\/div>\n\n\n\n<div id=\"col-gmeb49b1\" class=\"wp-block-gutentor-m4-col col-gmeb49b1 gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gmeb49b1\" class=\"section-gmeb49b1 gutentor-col-wrap\">\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-center speaker-heading has-white-color has-text-color\"><\/h3>\n<\/div><\/div>\n<\/div><\/div><\/section>\n<\/div><\/section>\n<\/div><\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":10,"featured_media":30326,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[29],"class_list":["post-30323","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-video","tag-prescient-therapeutics"],"gutentor_comment":0,"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prescient Therapeutics: Investor Briefing - PTX Therapeutics<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prescient Therapeutics: Investor Briefing - PTX Therapeutics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/\" \/>\n<meta property=\"og:site_name\" content=\"PTX Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-31T05:36:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-31T05:38:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png\" \/>\n\t<meta property=\"og:image:width\" content=\"650\" \/>\n\t<meta property=\"og:image:height\" content=\"360\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Daniella Watson\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Daniella Watson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/\"},\"author\":{\"name\":\"Daniella Watson\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d\"},\"headline\":\"Prescient Therapeutics: Investor Briefing\",\"datePublished\":\"2025-03-31T05:36:52+00:00\",\"dateModified\":\"2025-03-31T05:38:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/\"},\"wordCount\":293,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png\",\"keywords\":[\"Prescient Therapeutics\"],\"articleSection\":[\"Video\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/\",\"name\":\"Prescient Therapeutics: Investor Briefing - PTX Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png\",\"datePublished\":\"2025-03-31T05:36:52+00:00\",\"dateModified\":\"2025-03-31T05:38:00+00:00\",\"author\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d\"},\"breadcrumb\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/#primaryimage\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png\",\"contentUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png\",\"width\":650,\"height\":360},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prescient Therapeutics: Investor Briefing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\",\"name\":\"PTX Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d\",\"name\":\"Daniella Watson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g\",\"caption\":\"Daniella Watson\"},\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/daniella\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prescient Therapeutics: Investor Briefing - PTX Therapeutics","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Prescient Therapeutics: Investor Briefing - PTX Therapeutics","og_url":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/","og_site_name":"PTX Therapeutics","article_published_time":"2025-03-31T05:36:52+00:00","article_modified_time":"2025-03-31T05:38:00+00:00","og_image":[{"width":650,"height":360,"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png","type":"image\/png"}],"author":"Daniella Watson","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Daniella Watson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/#article","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/"},"author":{"name":"Daniella Watson","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d"},"headline":"Prescient Therapeutics: Investor Briefing","datePublished":"2025-03-31T05:36:52+00:00","dateModified":"2025-03-31T05:38:00+00:00","mainEntityOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/"},"wordCount":293,"commentCount":0,"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png","keywords":["Prescient Therapeutics"],"articleSection":["Video"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/","name":"Prescient Therapeutics: Investor Briefing - PTX Therapeutics","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/#primaryimage"},"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png","datePublished":"2025-03-31T05:36:52+00:00","dateModified":"2025-03-31T05:38:00+00:00","author":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d"},"breadcrumb":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/#primaryimage","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png","contentUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3.png","width":650,"height":360},{"@type":"BreadcrumbList","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing-31-mar\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/template.reachmarkets.com.au\/investorportal\/"},{"@type":"ListItem","position":2,"name":"Prescient Therapeutics: Investor Briefing"}]},{"@type":"WebSite","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/","name":"PTX Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d","name":"Daniella Watson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g","caption":"Daniella Watson"},"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/daniella\/"}]}},"_links":{"self":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/30323","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/comments?post=30323"}],"version-history":[{"count":3,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/30323\/revisions"}],"predecessor-version":[{"id":30340,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/30323\/revisions\/30340"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media\/30326"}],"wp:attachment":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media?parent=30323"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/categories?post=30323"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/tags?post=30323"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}